All In Biotech

Drug Trial Radar · NCT06244316

A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.

A 4-Week, Phase II, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study With 4 Weeks of Follow-Up to Evaluate Safety and Efficacy of a New Formulation of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution at Two Different Concentrations in Patients With Dry Eye Disease

Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 317 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

317

Actual

Start

Jan 22, 2024

Primary completion

Dec 4, 2024

Study completion Dec 4, 2024

Sponsor

Lead sponsor
Dompé Farmaceutici S.p.AIndustry
Sponsor type
Industry
First posted
Feb 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary objective • To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over vehicle in the improvement of ocular symptoms of dry eye in participants with dry eye disease (DED) Key secondary objectives * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in increasing the number of participants with improved reflex tear production as compared to vehicle at week 4 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving reflex tear production as compared to vehicle at week 4 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving ocular surface integrity (corneal epitheliopathy) as compared to vehicle at week 4 Secondary objectives * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving reflex tear production as compared to vehicle at week 8 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving tear film stability as compared to vehicle at weeks 4 and 8 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving ocular surface integrity (corneal and conjunctival epitheliopathy) as compared to vehicle at weeks 4 and 8 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving the severity and frequency of dry eye symptoms as compared to vehicle at weeks 4 and 8 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving dry eye symptoms as compared to vehicle at week 4 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving associated symptoms in DED as compared to vehicle at weeks 4 and 8 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving the quality of life in participants with DED as compared to vehicle at weeks 4 and 8 * To evaluate the efficacy of the new formulation of rhNGF ophthalmic solution in improving best corrected visual acuity in DED as compared to vehicle at weeks 4 and 8 Safety objectives * To evaluate safety/tolerability of the new formulation of rhNGF ophthalmic solution * To evaluate safety of the new formulation of rhNGF ophthalmic solution * To evaluate tolerability of the new formulation of rhNGF ophthalmic solution

Conditions

  • Dry Eye Disease

Interventions

  • rhNGF 5 μg/mLDrug

    1 drop of rhNGF ophthalmic solution at 5 μg/mL in each eye TID, at approximately 6-hour intervals, for 4 weeks of treatment.

  • rhNGF 10 μg/mLDrug

    1 drop of rhNGF ophthalmic solution at 10 μg/mL in each eye TID, at approximately 6-hour intervals, for 4 weeks of treatment.

  • Vehicle (Placebo solution)Drug

    Eye drop solution, containing no rhNGF. 1 drop of vehicle in each eye TID at approximately 6-hour intervals, for 4 weeks of treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline to Week 8 in Symptoms of Dry Eye Assessed by Symptom Assessment in Dry Eye (SANDE) Global ScoreTime frame: Week 8 (V5)

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Eye Center

    Chandler, Arizona

  • East West Eye Institute

    Torrance, California

  • Vision Institute - Fontanero St

    Colorado Springs, Colorado

  • Sibia Eye Institute

    Boynton Beach, Florida

  • Eye Consultants of Atlanta

    Atlanta, Georgia

  • New England Eye Center - Boston

    Boston, Massachusetts

  • Eye Associates of North Jersey

    Dover, New Jersey

  • The Scheie Eye Institute

    Philadelphia, Pennsylvania

  • Total Eye Care PA

    Memphis, Tennessee

  • Toyos Clinic

    Nashville, Tennessee

  • Azienda Ospedaliera Universitaria Policlinico G Martino

    Messina, Italy

  • Ospedale S. Giuseppe Multimedica

    Milan, Italy

  • Fondazione Policlinico Universitario Campus Bio-Medico di Roma

    Roma, Italy

  • Azienda Ospedaliero Universitario Policlinicol Umberto I

    Roma, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.